Supercede Therapeutics

Executive Summary

Supercede Therapeutics is a Boston-based biotechnology company founded in 2022 that leverages artificial intelligence and machine learning to accelerate small molecule drug discovery. The company focuses on developing novel therapeutics targeting clinically validated pathways in renal, metabolic, neurological, and other disease areas. By integrating bioinformatics and AI/ML, Superede aims to increase the efficiency of drug discovery and reduce the time to deliver treatments to patients. Currently in the pre-clinical stage, the company is building a pipeline of candidates that address high-need indications. Given its founding date and early stage, Superede represents an emerging player in the AI-driven drug discovery space, with potential for significant value creation as it advances its programs toward the clinic.

Upcoming Catalysts (preview)

• Q3 2026Lead Optimization Completion for Lead Candidate40% success
• Q4 2026Announcement of Strategic Partnership or Collaboration35% success
• Q1 2027Preclinical Data Presentation at Scientific Conference50% success